Companies Supporting Research to Advance the Treatment of Endocrine Diseases

Spruce is a privately held company that has completed its Series A financing round, raising $20M to advance the clinical development of our lead drug candidate, SPR001. Our investors are:

Novo: Bringing promising ideas to life.

Novo is one of the key players in the international life science investment industry, and is currently investing in 76 portfolio companies. Our portfolio spans the entire range of life science development. From budding ideas that need financial and commercial nurturing, to well-established biomedical and bioindustrial companies that call for significant capital and a long term investor to accelerate growth.

Visit Website +

Rivervest: Investing in life science innovation.

RiverVest Venture Partners® focuses exclusively on innovations in life sciences, a field in which our team has significant research, clinical, operational and investment expertise. Our team’s deep domain experience allows us to identify, found and actively incubate promising life science companies, particularly in the medical device and biopharmaceutical industries. We provide practical advice and strategic leadership to help entrepreneurs drive early-stage companies forward.

Visit Website +

Now Enrolling Patients for

Congenital Adrenal Hyperplasia Clinical Trials 2017

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new therapy for CAH. To take our pre-screener and see if you may qualify, visit www.CAHclinicaltrial.com

Learn More

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.